mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in...
Cardiac ventricles in which vaccine was detected had healing myocardial injury at the time of vaccination and had more myocardial macrophages than the cardiac ventricles in which vaccine was not detected. These results suggest that SARS-CoV-2 mRNA vaccines routinely persist up to 30 days from ...
近日,由嘉晨西海生物公司研发的一款肿瘤新抗原mRNA疫苗——JCXH-211,获得美国FDA的IND批准,它是全球首款表达细胞因子的自复制mRNA产品,同时也是国内mRNA生物技术公司首次获得美国FDA的IND批件,也标志着国内mRNA药物或疫苗首次成功出海欧美主要...
2023年3月21日和12月1日,石药集团自主研发的新型冠状病毒mRNA疫苗(含BA.5核心突变位点)(产品代号:SYS6006,商品名:度恩泰®),以及第二代新冠mRNA疫苗——二价新冠病毒mRNA疫苗(XBB.1.5/BQ.1)(SYS6006.32)相继在国内获得紧急使用授权,并分别成为...
[2] Kim SC, Sekhon SS, Shin WR, et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1-8. [3] Szabó GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: Platforms and current developments. Mol ...
The TheraPure portfolio of products can also be custom-formulated to meet your process development and manufacturing needs. Many of these products have been consistently manufactured at a global scale and have been successfully used in several mRNA thera...
BioNTech has established a diversified clinical oncology pipeline of more than 20 clinical programs along mRNA-based therapeutic cancer vaccines, targeted therapies comprising cell therapies and ADCs, and novel immunomodulators in unmet medical need solid tumor indic...
mRNA vaccine, type of vaccine that uses a synthetic version of a molecule known as messenger RNA (mRNA) to instruct cells in the body to produce a specific protein that trains the immune system to recognize and destroy the targeted disease-associated entity. Vaccines based on mRNA rely primaril...
COVID-19 mRNA vaccines; myo-pericarditis and COVID-19 mRNA vaccines; multisystem inflammatory syndrome and COVID-19 mRNA vaccines; arrhythmias and COVID-19 mRNA vaccines; pathogenesis of myocarditis following COVID-19 mRNA vaccines; MIS-A; MIS-C; MIS-V; myocarditis; COVID-19 mRNA vaccine ...
mRNA vaccines is likely to be in the tens of thousands range. Given that different manufacturers are pursuing different strategies to optimize their candidate vaccines, conclusions from one candidate may not be generalizable. Therefore, it is likely that each candidate vaccine will have to ...